GlassScriptPhysician profile
Taylor Sethna
NPI 1891300687
$6,700.99
in general payments reported to CMS, 2019-2025
18 companies · $1,914 in 2025
The $1,914 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.79 · 2022: $373 · 2023: $1,278 · 2024: $3,115 · 2025: $1,914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,307.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,511.54 | 2021-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Alkermes, INC. | $818.23 | 2022-2025 | Lybalvi, Aristada |
| Teva Pharmaceuticals USA, INC. | $808.65 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $538.00 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $520.01 | 2024-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Vanda Pharmaceuticals INC. | $462.44 | 2024-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $412.70 | 2024-2025 | Ingrezza |
| Abbvie INC. | $406.10 | 2024-2025 | |
| Lundbeck LLC | $388.09 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $296.08 | 2025 | Cobenfy |
| Axsome Therapeutics, INC. | $171.02 | 2023-2025 | Auvelity |
| Validus Pharmaceuticals LLC | $117.64 | 2023-2024 | Equetro |
| Takeda Pharmaceuticals U.S.A., INC. | $84.03 | 2024 | Trintellix |
| Nevro Corp. | $42.75 | 2023 | Senza |
| Idorsia Pharmaceuticals US INC | $39.69 | 2024 | Quviviq |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $33.49 | 2023 | Azstarys |
| Ironshore Pharmaceuticals INC. | $33.36 | 2023 | Jornay Pm |
| Almatica Pharma LLC | $17.17 | 2025 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Sethna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.